% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wang:293318,
author = {S. E. Wang and V. Viallon and M. Lee and N. Dimou and F.
Hamilton and C. Biessy and T. O'Mara and M. Kyrgiou and E.
J. Crosbie and T. Truong and G. Severi and R. Kaaks$^*$ and
R. T. Fortner$^*$ and M. B. Schulze and B. Bendinelli and S.
Sabina and R. Tumino and C. Sacerdote and S. Panico and M.
Crous-Bou and M.-J. Sánchez and A. Aizpurua and D. R.
Palacios and M. Guevara and R. C. Travis and K. K. Tsilidis
and A. Heath and J. Yarmolinsky and S. Rinaldi and M. J.
Gunter and L. Dossus},
title = {{C}irculating inflammatory and immune response proteins and
endometrial cancer risk: a nested case-control study and
{M}endelian randomization analyses.},
journal = {EBioMedicine},
volume = {108},
issn = {2352-3964},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2024-01871},
pages = {105341},
year = {2024},
abstract = {Inflammation and immune dysregulation are hypothesized
contributors to endometrial carcinogenesis; however, the
precise underlying mechanisms remain unclear.We measured
pre-diagnostically 152 plasma protein biomarkers in 624
endometrial cancer case-control pairs nested within the
European Prospective Investigation into Cancer and Nutrition
(EPIC) cohort. Odds ratios (ORs) were estimated using
conditional logistic regression, accounting for confounding
and multiple comparisons. Proteins considered as associated
with endometrial cancer risk were further tested in a
two-sample Mendelian randomization (MR) analysis using
summary data from the UK Biobank (n = 52,363) and the
Endometrial Cancer Association Consortium (12,270 cases and
46,126 controls).In the EPIC nested case-control study, IL-6
[OR per NPX (doubling of concentration) = 1.28 $(95\%$
confidence interval (CI) 1.03-1.57)], HGF [1.48
(1.06-2.07)], PIK3AP1 [1.22 (1.00-1.50)] and CLEC4G [1.52
(1.00-2.32)] were positively associated; HSD11B1 [0.67
(0.49-0.91)], SCF [0.68 (0.49-0.94)], and CCL25 [0.80
(0.65-0.99)] were inversely associated with endometrial
cancer risk; all estimates had multiple comparisons adjusted
P-value > 0.05. In complementary MR analysis, IL-6 [OR per
inverse-rank normalized NPX = 1.19 $(95\%$ CI 1.04-1.36)]
and HSD11B1 [0.91 (0.84-0.99)] were associated with
endometrial cancer risk.Altered IL-6 signalling and reduced
glucocorticoid activity via HSD11B1 might play important
roles in endometrial carcinogenesis.Funding for
$IIG_FULL_2021_008$ was obtained from Wereld Kanker
Onderzoek Fonds (WKOF), as part of the World Cancer Research
Fund International grant programme; Funding for $INCA_15849$
was obtained from Institut National du Cancer (INCa).},
keywords = {Endometrial cancer (Other) / HSD11B1 (Other) /
Interleukin-6 (Other) / Mendelian randomisation (Other) /
Proteomics (Other)},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39278107},
doi = {DOI:10.1016/j.ebiom.2024.105341},
url = {https://inrepo02.dkfz.de/record/293318},
}